Volume 1, Issue 2 ((Journal of Clinical and Basic Research (JCBR) 2017)
jcbr 2017, 1(2): 36-43 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Marjani A. Metabolic Syndrome and Diabetes: A Review. jcbr 2017; 1 (2) :36-43
URL: http://jcbr.goums.ac.ir/article-1-58-en.html
URL: http://jcbr.goums.ac.ir/article-1-58-en.html
Abstract: (5496 Views)
The prevalence of metabolic syndrome is increasing worldwide. Several factors such as hyperglycemia are associated with risk of developing metabolic syndrome. Metabolic syndrome is a clinical tool for identification of subjects at risk of diseases such as type 2 diabetes mellitus, which could be a predictor of metabolic syndrome. There may be an association between diabetes, metabolic syndrome and cardiovascular morbidity and mortality. This study aimed to review the literature on diabetes, as a component of metabolic syndrome.
Article Type: Research |
References
1. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,et al. Harmonizingthe metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and international association for the study of obesity. Circulation. 2009; 120 (16): 1640–1645. [DOI:10.1161/CIRCULATIONAHA.109.192644]
2. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome — a new worldwide definition. The Lancet. 2005; 366 (9491):1059–1062. [DOI:10.1016/S0140-6736(05)67402-8]
3. Kylin E. Studienueber das Hypertonie-Hyperglyca \"mie-Hyperurika\" miesyndrom. ZentralblattfuerInnereMedizin. 1923; 44: 105–127.
4. Vague J. Sexual differentiation. A factor affecting the forms of obesity. Presse Medicale. 1947; 30: 339–340.
5. Avogaro P and G. Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia. 1965; 1: 137.
6. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37 (12):1595–1607. [DOI:10.2337/diab.37.12.1595]
7. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine. 1989; 149 (7): 1514–1520. [DOI:10.1001/archinte.1989.00390070054005]
8. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA and Stern MP. Prospective analysis of the insulinresistance syndrome (Syndrome X). Diabetes. 1992; 41 (6):715–722. [DOI:10.2337/diab.41.6.715]
9. Eckel RH, Grundy SM and Zimmet PZ. The metabolic syndrome. The Lancet. 2005; 365 (9468):1415–1428. [DOI:10.1016/S0140-6736(05)66378-7]
10. Alberti KG and Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine. 1998; 15(7): 539–553.
https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S [DOI:10.1002/(SICI)1096-9136(199807)15:73.0.CO;2-S]
11. Balkau B and Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabetic Medicine. 1999; 16 (5): 442–443. [DOI:10.1046/j.1464-5491.1999.00059.x]
12. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association. 2001; 285 (19): 2486–2497. [DOI:10.1001/jama.285.19.2486]
13. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocrine Practice. 2003; 9 (3): 237–252.
14. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome, 2005; http://www.idf.org/metabolic-syndrome.
15. Desroches S and Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome. Applied Physiology, Nutrition and Metabolism. 2007; 32 (1): 23–32. [DOI:10.1139/h06-095]
16. Kolovou GD, Anagnostopoulou KK, SalpeaKD, and Mikhailidis DP. The prevalence of metabolic syndrome in various populations. The American Journal of the Medical Sciences. 2007; 333 (6): 362–371. [DOI:10.1097/MAJ.0b013e318065c3a1]
17. Cameron AJ, Shaw JE and ZimmetPZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America. 2004; 33 (2): 351–375. [DOI:10.1016/j.ecl.2004.03.005]
18. Park Y-W, Zhu S, Palaniappan L, Heshka S,CarnethonMR, and Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Archives of Internal Medicine. 2003; 163 (4): 427–436. [DOI:10.1001/archinte.163.4.427]
19. Ponholzer A, Temml C, Rauchenwald M, Marszalek M, and Madersbacher S. Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women? International Journal of Impotence Research. 2008; 20 (1):100–104. [DOI:10.1038/sj.ijir.3901605]
20. Marjani A, Mojerloo M. The metabolic syndrome in type 2 diabetic subjects in Gorgan, Iran. J Pak Med Assoc. 2011;61(5):458-461.
21. Marjani A and Shirafkan A. The Metabolic Syndrome in Type 2 Diabetic Patients in Gorgan: According To NCEP ATP III and IDF Definitions. Advances in Biological Research. 2011; 5 (4): 200-205. [DOI:10.1016/j.dsx.2012.02.009]
22. Marjani A, Hezarkhani S and Shahini N. Prevalence of Metabolic Syndrome among Fars Ethnic Women in North East of Iran. World Journal of Medical Sciences. 2012; 7(1: 17-22.
23. Marjani A, Shahini N, AghAtabay O, GhiyasTabari R. Prevalence of Metabolic Syndrome among Sistanee Ethnic Women. Advanced Studies in Biology. 2012; 8: 363 – 372.
24. Kim HM, Park J, Ryu SY, Kim J. The effect of menopause on the metabolic syndrome among Korean women: the Korean National Health and Nutrition Examination Survey. Diabetes Care. 2007; 30(3):701-706. [DOI:10.2337/dc06-1400]
25. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365(9468):1398-1405. [DOI:10.1016/S0140-6736(05)66375-1]
26. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2010;65(3):262-266. [DOI:10.1016/j.maturitas.2009.11.004]
27. Ainy E, Mirmiran P, ZahediAsl S, Azizi F. Prevalence of metabolic syndrome during menopausal transitionTehranian women: Tehran Lipid and Glucose Study (TLGS). Maturitas. 2007;58(2):150-155. [DOI:10.1016/j.maturitas.2007.07.002]
28. Deibert P, Konig D, VitolinsMZ, Landmann U, Frey I, Zahradnik HP, Berg A. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre- versus postmenopausal women. Nutrition Journal. 2007;6 (1):31. [DOI:10.1186/1475-2891-6-31]
29. Figueiredo Neto JA, Figueredo ED, Barbosa JB, Barbosa Fd, Costa GR, Nina VJ, Nina RV. Metabolic syndrome and menopause: cross-sectional study in gynecology clinic. Arquivos Brasileiros de Cardiologia. 2010;95(3):339-345. [DOI:10.1590/S0066-782X2010005000094]
30. Heidari R, Sadeghi M, Talaei M, Rabiei K, Mohammadifard N, Sarrafzadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. DiabetolMetabSyndr. 2010; 2: 59. [DOI:10.1186/1758-5996-2-59]
31. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, De Gregorio M, et al. Racial differences in the relation between blood pressure and insulin resistance. New England Journal of Medicine. 1991;324(11):733–9. [DOI:10.1056/NEJM199103143241105]
32. Bentley-Lewis R, Koruda K, SeelyEW. The metabolic syndrome in women. Nature clinical practice. Endocrinology & metabolism. 2007;3(10):696–704. [DOI:10.1038/ncpendmet0616]
33. Grundy SM. Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk. Journal of the American College of Cardiology 2012; 59 (7): 635–43 [DOI:10.1016/j.jacc.2011.08.080]
34. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31 Suppl 1:S12-54. [DOI:10.2337/dc08-S012]
35. Zimmet P, Alberti KG, Shaw S. Global and societal implications of diabetes epidemic. Nature. 2001;414 (6865):782-7. [DOI:10.1038/414782a]
36. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (erratum in: Circulation. 2005; 112:2735–52. [DOI:10.1161/CIRCULATIONAHA.105.169404]
37. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Medica. 2005;47:201–10.
38. Hanley AJ, Wagenknecht LE, D\'Agostino RB Jr., Zinman B, Haffner SM. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes. 2003;52:2740 –7. [DOI:10.2337/diabetes.52.11.2740]
39. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27 (11):2676–81. [DOI:10.2337/diacare.27.11.2676]
40. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007; 30 (1): 8 –13. [DOI:10.2337/dc06-1414]
41. Lebovitz HE. Insulin resistance: a common link between type 2diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism. 2006;8 (3):237-49. [DOI:10.1111/j.1463-1326.2005.00521.x]
42. Thomas JE, Foody JM. The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy. Journal of the CardioMetabolic Syndrome. 2007;2(2):108-13. [DOI:10.1111/j.1559-4564.2007.06046.x]
43. He Z, King GL. Microvascular complications of diabetes. Endocrinology and Metabolism Clinics of North America. North Am 2004;33 (1) :215–38, xi–xii.
44. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Research. 2009;335 (1):165– 89. [DOI:10.1007/s00441-008-0685-6]
45. American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 2013;36(Suppl. 1):S11–66. [DOI:10.2337/dc13-S011]
46. Wang YW, Sun GD, Sun J, Liu SJ, Wang J, XuXH, et al. Spontaneous Type 2 diabetic rodent models. Journal of Diabetes Research.2013.http://dx.doi.org/10.1155/2013/401723. [DOI:10.1155/2013/401723]
47. Metascreen Writing Committee, Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A: The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes care. 2006; 29 (12):2701-07. [DOI:10.2337/dc06-0942]
48. Cheng Y, Zhang H, Chen R, Yang F, Li W, Chen L, et al. Cardiometabolic Risk Profiles Associated with Chronic Complications in Overweight and ObeseType 2 Diabetes Patients in South China. PLoS ONE. 2014; 9(7): e101289. [DOI:10.1371/journal.pone.0101289]
49. Isomaaa B, Henricsson M, Almgren P, Tuomi T, TaskinenMR, Groop L. The metabolic syndrome nfluences the risk of chronic complications in patients with type II diabetes. Diabetologica. 2001; 44 (9):1148-54. [DOI:10.1007/s001250100615]
50. Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. Israel Medicine Association Journal.2006; 8 (6):378-82.
51. Raman R, Gupta A, Pal SS. Prevalence of MS and its influence on microvascular complications in the Indian population with Type 2 Diabetes Mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 14).Diabetology and metabolic syndrome. 2010; 2:67. [DOI:10.1186/1758-5996-2-67]
52. Pang C, Jia L, Hou X, Gao X, Liu W, Bao Y, et al. The Significance of Screening for Microvascular Diseases in Chinese Community-Based Subjects with Various Metabolic Abnormalities. PLoS ONE. 2014;9(5):e97928. [DOI:10.1371/journal.pone.0097928]
53. Iwasaki T, Togashi Y, Ohshige K. Neither the presence of MS as defined by the IDF guideline nor an increased waist circumference increased the risk of microvascular normacrovascular complications in Japanese patients with type 2 Diabetes. Diabetes Research Clinical Practice 2008;79(3):427-32. [DOI:10.1016/j.diabres.2007.10.035]
54. Carole AC, Christine CJ, Retnakaran R, Holman RR. Impact of the metabolic syndromen Macrovascular and Microvascular Outcomes in Type 2 Diabetes Mellitus United Kingdom Prospective Diabetes Study 78. Circulation. 2007;116:2119-2126. [DOI:10.1161/CIRCULATIONAHA.107.733428]
55. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. Preventive Cardiology. 2005; 8 (1): 47–54. [DOI:10.1111/j.1520-037X.2005.4073.x]
56. Deen D. Metabolic syndrome: time for action. The American Family Physician. 2004; 69 (12): 2875–2887.
57. Bellentani S, Grave RD, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008; 47 (2): 746–754. [DOI:10.1002/hep.22009]
58. Donato KA. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Archives of Internal Medicine. 1998; 158 (17):1855–1867. [DOI:10.1001/archinte.158.17.1855]
59. Duncan GE, Perri MG, TheriaqueDW, Hutson AD, Eckel RH, Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care. 2003; 26 (3): 557–562. [DOI:10.2337/diacare.26.3.557]
60. Van Gaal LF, Wauters MA, De LeeuwIH. The beneficial effects of modest weight loss on cardiovascular risk factors. International Journal of Obesity. 1997; 21(supplement 1): S5–S9.
61. Wing RR, Koeske R, EpsteinLH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Archives of Internal Medicine. 1987; 147 (10): 1749–1753. [DOI:10.1001/archinte.1987.00370100063012]
62. Ross R, Janssen I, Dawsonet J, Kungl AM, Kuk JL, Wong SL, al. Exercise-inducedreduction in obesity and insulin resistance in women: a randomized controlled trial. Obesity Research. 2004; 12 (5):789–798. [DOI:10.1038/oby.2004.95]
63. Haslam DW and James WPT. Obesity. The Lancet. 2005; 366 (9492): 1197–1209. [DOI:10.1016/S0140-6736(05)67483-1]
64. Toumilheto J, Lindstrom J, Eriksson JG, VaLLe TT, Hamalainen H, Ilanne-Parikka P,et al. Prevention of type 2 diabetes mellitus with lifestyle intervention or metformin. The New England Journal of Medicine 2001; 344 (18): 1343–1350. [DOI:10.1056/NEJM200105033441801]
65. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RE, Lachin JM, Walker EK, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 2002; 346 (6): 393–403. [DOI:10.1056/NEJMoa012512]
66. Jenkins DJ, Kendall CW, Augustin LS, Franceschi S, Hamidi M, Marchie A, et al. Glycemic index: overview of implications in health and disease. The American Journal of Clinical Nutrition 2002; 76 (1): 266S–273S.
67. McKeown NM, MeigsJB, Liu S, Saltzman E, Wilson PWF, and Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care. 2004; 27 (2): 538–546. [DOI:10.2337/diacare.27.2.538]
68. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report. Circulation. 2002; 106 (25): 3143–3421.
69. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the JointNational Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. Journal of the AmericanMedical Association. 2003; 289 (19): 2560–2572. [DOI:10.1001/jama.289.19.2560]
70. American Diabetes Association. Clinical practice recommendations 2005.Diabetes Care. 2005; 28 (supplement 1): S1–79.
71. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. National Institutes of Health. Obesity Research. 1998; 6(supplement 2): 51S–209S.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).